Whalesbook
Aise Bhaaga Stock, Toh Kya Naye Targets?
Dekho, 11 May 2026 ke aas-paas Tata Consumer Products ka share lagbhag 7% bhaga tha aur do saal ka naya high bana liya tha. Iska reason tha Q4 aur poore FY26 ke results jo analysts ke expectations se bhi acche aaye. Company ne poore saal mein ₹20,290.43 Crore ka consolidated revenue record kiya, jo 15.17% upar hai. Net profit bhi 20.18% badh kar ₹1,546.80 Crore ho gaya. Aur toh aur, management FY27 ke liye bhi double-digit revenue growth expect kar raha hai aur EBITDA margin bhi 50-70 basis points badhne ka andaza hai. Shareholders ke liye ₹10 per share ka dividend bhi recommend kiya gaya hai.
Par Bhai, Valuation Ka Kya Scene Hai?
Ab aata hai asli point. Jis P/E ratio (77x-79x) par Tata Consumer Products trade kar raha hai, woh apne bade rivals ke saamne bahut hi zyada hai. Hindustan Unilever (HUL) 33x-50x par hai, Dabur India 43-45x par, aur ITC toh sirf 11-19x par hai. Yeh bade gap ka matlab hai ki investors company ke future growth aur AI adoption se kaafi umeed lagaaye baithe hain. Company AI ko apni supply chain, demand forecasting aur customer engagement mein use karke operational efficiency badhane ki koshish mein hai.
FMCG Sector Mein Tension Kyu Hai?
Asal mein, poora FMCG sector filhaal thoda pressure mein hai. Input costs mein tez izafa ho raha hai, jiske chalte FY26 ke liye sector growth ka forecast 3% tak aa gaya hai. Global tensions aur crude oil prices ke badhne se (~$106.19/barrel tak), WPI April 2026 mein 8.3% tak pahunch gaya tha. Isse logistics aur raw material ke daam badh rahe hain, jo sidha margins par asar daal sakte hain. Tata Consumer Products apni pricing power se ise manage karne ki koshish kar raha hai, par rural demand ka recovery aur inflation ka potential impact bhi ek challenge hai. Pichle teen saalon mein company ka Return on Equity (ROE) bhi average 7.56% raha hai aur FY26 mein ₹16.17 Crore ke kuch exceptional items ne bhi performance ko affect kiya tha.
Analysts Kya Bol Rahe Hain?
Bahut sare analysts abhi bhi Tata Consumer Products ko lekar optimistic hain. LSEG ke data ke mutabik, 26 mein se zyada tar analysts 'buy' rating de rahe hain aur median target price ₹1,315 rakha hai. Yeh dikhata hai ki current levels se bhi upside ki sambhavna hai. Company ka AI strategy aur premium/health products par focus future growth drivers ban sakte hain. Management toh FY26 se FY29 ke beech sales mein 10% aur earnings mein 18% ka CAGR expect kar raha hai. Par yeh sabhi ambitious plans tabhi kaam karenge jab company apna valuation justify kar payegi aur sector peers se consistently achha perform karegi.